Australia Diabetes Devices Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia diabetes devices market is moving from manual testing and injections towards connected sensors and pumps. Funding rules, not consumer demand, set the pace, because subsidy decisions decide who can afford a sensor or a pump.

Three forces are shaping the market: a large and growing patient base of about 1.5 million diagnosed Australians; subsidised access that already covers continuous glucose monitoring for type 1 diabetes but not yet for most people with type 2; and the arrival of tubeless pods and 15-day sensors that raise the value of each patient.

In December 2025 the NDSS began subsidising the FreeStyle Libre 3 Plus sensor. In February 2026 diabetes organisations asked the Federal Budget for AUD 298.95 million for automated insulin delivery, and in May 2026 the government only noted wider sensor access.

Key Market Trends and Insights

• Large patient base: About 1.5 million Australians live with diagnosed diabetes, and diabetes costs the health system an estimated AUD 14.2 billion a year, which keeps device funding on the political agenda.
• Sensor penetration: More than 70% of Australians with type 1 diabetes now use a glucose sensor, according to Breakthrough T1D in February 2026, so growth depends on type 2 access.
• Pump access gap: Only about 30% of Australians with type 1 diabetes can access an insulin pump, and the fully subsidised program funds just 395 places for young people.
• Pending subsidy decisions: The sector sought AUD 106.48 million for sensors for 16,000 people with type 2 diabetes, yet the government only noted that recommendation in May 2026.

Australia Diabetes Devices Market Size and Forecast

The market is shifting from blood glucose meters and syringes towards sensors, pods and automated insulin delivery systems that reduce daily management effort. Continuous glucose monitors lead in value because every insulin-treated patient who qualifies for a subsidy buys sensors continuously, while insulin pumps grow fastest as funding for automated systems is debated. Type 2 diabetes expands quickest as eligibility widens, and online and direct sales gain share from pharmacy counters. New South Wales remains the largest region by patient numbers, and Queensland grows quickest on population inflow. Tighter integration between sensors and pumps, simpler wearables and any decision to widen subsidies point to a durable change in product mix rather than a short cycle, even though price scrutiny and tendering remain risks.

Key Takeaways: Australia Diabetes Devices Market

Subsidy Policy Sets the Growth Ceiling

Revenue is on course to more than double, from USD 450.00 million in 2025 to USD 971.52 million in 2035 at an 8.0% CAGR. Wider coverage is the main swing factor: the sector asked in February 2026 for AUD 405 million over four years, yet the May 2026 government response only noted wider sensor access.

Pumps and Type 2 Sensors Lead Growth

Continuous glucose monitors hold the largest share, but Insulin Pumps and Consumables grow at an estimated 11.8% CAGR and Type 2 Diabetes at an estimated 10.4% CAGR through 2035. Insulet confirmed in March 2025 that Omnipod 5 was available in Australia, while the NDSS added Libre 3 Plus for YpsoPump users in December 2025.

Sensor Lifespans and Pumps Reshape Spending

Fifteen-day sensors and tubeless pods raise annual value per patient, while meter and strip sales stay flat. Payers and patients are watching co-payments closely.

• Dexcom G7 joined the NDSS in March 2025 at a AUD 11.60 co-payment per sensor
• Libre 3 Plus joined in December 2025 at AUD 17.35 per sensor
• Type 2 users without subsidy spend AUD 2,000 to AUD 4,000 a year

Australia Diabetes Devices Market Report Summary

Key Insight

Sensors and automated pumps are displacing meters and syringes as subsidies widen. New South Wales leads by patient numbers, and Queensland grows fastest as its population expands.

Key Trends in the Australia Diabetes Devices Market

The Australia diabetes devices market is being reshaped by sector budget requests, a cautious government response, new subsidised sensors and moves towards automated insulin delivery.

May 2026 - Government Notes Wider Sensor Access but Keeps Existing Funding

• The limbic reported on 26 May 2026 that the government supported 9 of 23 inquiry recommendations in principle.
• Expanding sensor subsidies to type 2 and gestational diabetes was only noted, with the response citing AUD 682.3 million of existing funding.
• Suppliers should expect no near-term widening of eligibility, so growth leans on type 1 upgrades and private purchases.

March 2026 - MSAC Defers Advice on Type 2 Sensor Funding Applications

• The limbic reported on 11 March 2026 that the Medical Services Advisory Committee deferred advice on applications by Abbott Australasia and Australasian Medical & Scientific.
• The applications sought public funding of Dexcom ONE+ and FreeStyle Libre for certain people with type 2 diabetes.
• The committee asked for more data, which delays a larger addressable market.

February 2026 - Diabetes Organisations Seek AUD 405 Million for Technology Access

• Diabetes Australia and partners lodged two joint 2026-27 Budget submissions on 24 February 2026.
• One asks AUD 298.95 million over four years for automated insulin delivery for 38,000 people with type 1 diabetes.
• The other asks AUD 106.48 million for sensors for 16,000 people with type 2 and other insulin-treated diabetes.

December 2025 - NDSS Subsidises FreeStyle Libre 3 Plus for YpsoPump Users

• The NDSS announced on 17 November 2025 that the 15-day sensor would be subsidised from 1 December 2025.
• It works only with the mylife YpsoPump running CamAPS FX, and co-payment is AUD 17.35 per sensor.
• Pairing a sensor with one pump shows suppliers using subsidy listings to lock in automated insulin delivery users.

Key Insight

Sector budget requests, cautious government responses and pump-linked sensor listings are the main forces, while delayed decisions on wider eligibility remain the biggest source of uncertainty.

Recent Market Developments in the Australia Diabetes Devices Market

Recent developments, presented from the most recent, show Ypsomed app changes, the Medtronic diabetes spin-off, sensor launches and the arrival of tubeless pods.

December 2026 - Ypsomed to Phase Out the mylife App as myLoop Takes Over

• Ypsomed will close the mylife App in Australia on 1 December 2026, according to Diabetes Victoria.
• Digital therapy moves to the myLoop platform powered by CamAPS FX, with cloud users shifting to Glooko.
• The change pushes users with older equipment towards updated pumps and connected software.

December 2025 - Medtronic Files for MiniMed Listing and Launches 780G with Abbott Sensor

• Medtronic announced on 19 December 2025 that its diabetes business MiniMed had filed for an initial public offering.
• On 2 December 2025 Medtronic began a United States launch of the MiniMed 780G with the Abbott-made Instinct sensor.
• MiniMed plans to seek United States approval of its Fit patch pump by autumn 2026.

November 2025 - Dexcom Smart Basal Receives United States Clearance for Type 2 Diabetes

• Dexcom announced on 19 November 2025 that Smart Basal received clearance as a sensor-integrated basal insulin dosing optimiser.
• The software targets type 2 diabetes, the group Australian advocates want added to sensor subsidies.
• Australian availability is not yet confirmed, but it signals the direction of sensor-led care.

March 2025 - Insulet Makes Omnipod 5 Commercially Available in Australia

• Insulet announced on 18 March 2025 that Omnipod 5 was available in Australia with Dexcom G6 and G7 sensors.
• Support for Abbott's FreeStyle Libre 2 Plus was planned, which widens sensor choice.
• A tubeless, waterproof pod gives people who avoid tubing a new route to automated insulin delivery.

Key Insight

Software changes, new automated delivery launches and a corporate separation at a major pump maker show suppliers positioning for connected, sensor-led care through the forecast period.

Australia Diabetes Devices Industry Segmentation

The Expert Market Research’s report on the Australia Diabetes Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Product Type

• Continuous Glucose Monitors
• Insulin Pumps and Consumables
• Blood Glucose Meters and Strips
• Insulin Pens, Syringes and Needles
• Others

Continuous Glucose Monitors lead on value, in our estimate, because the NDSS has subsidised sensors for type 1 diabetes since Dexcom G7 listings began in March 2025 and Libre 3 Plus followed in December 2025. Insulin Pumps and Consumables grow fastest at an estimated 11.8% CAGR through 2035, as Omnipod 5 reached Australia in March 2025 and sector bids seek AUD 298.95 million for pumps. Blood Glucose Meters and Strips decline in share as sensors replace finger-pricks. Insulin Pens, Syringes and Needles grow steadily with the rising insulin-treated population, while Others cover lancets and accessories.

Market Breakup by Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational and Other Diabetes
• Others

Type 1 Diabetes leads in value, in our estimate, because more than 144,000 people have it and the subsidy covers their sensors. Type 2 Diabetes grows fastest at an estimated 10.4% CAGR through 2035, as the February 2026 submission asks for sensors for 16,000 insulin-treated people and out-of-pocket users already pay AUD 2,000 to AUD 4,000 a year. Gestational and Other Diabetes grows steadily, with pregnant women named as a priority group in the same February 2026 submissions.

Market Breakup by Distribution Channel

• Community Pharmacies and NDSS Access Points
• Hospitals and Specialist Clinics
• Online and Direct Sales
• Others

Community Pharmacies and NDSS Access Points lead, in our estimate, because subsidised sensors and pods are ordered there, and the NDSS confirmed ordering from 1 December 2025 for Libre 3 Plus. Hospitals and Specialist Clinics matter for initiation, as only authorised health professionals can update sensor access. Online and Direct Sales grows fastest at an estimated 10.0% CAGR through 2035, driven by subscription pump models and self-funded sensor buyers. Others include private health insurer and aged-care supply arrangements.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, as Australia's most populous state with the largest number of NDSS registrants, and it grows at an estimated 7.6% CAGR through 2035 from a mature base. Victoria follows at 7.9%, supported by a dense hospital and clinic network. Queensland is the fastest-growing region at an estimated 9.0%, on population inflow and rising type 2 prevalence. Western Australia grows at 8.6%, helped by remote-area telehealth. Others, covering the remaining states and territories, grow at 8.2%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Diabetes Devices Market

Competition combines global sensor makers, pump specialists and established meter suppliers selling through the NDSS and pharmacies. Entry barriers include Therapeutic Goods Administration approval, NDSS listing, pump and sensor compatibility, clinic training and reimbursement negotiations with government.

Dexcom

Dexcom, headquartered in San Diego, California, makes the G7 continuous glucose monitor and the ONE+ sensor sold in Australia. The NDSS began subsidising Dexcom G7 sensors on 1 March 2025 at a AUD 11.60 co-payment per 10-day sensor. In March 2026 the limbic reported that its ONE+ sensor was part of a pending application for type 2 funding. Its Smart Basal software received United States clearance in November 2025.

Abbott

Abbott, headquartered in Abbott Park, Illinois, sells the FreeStyle Libre range in Australia through Abbott Australasia. The NDSS began subsidising the 15-day FreeStyle Libre 3 Plus sensor on 1 December 2025 for people using the mylife YpsoPump with CamAPS FX, at AUD 17.35 per sensor. Abbott Australasia also sought type 2 funding for Libre, which the Medical Services Advisory Committee deferred, as reported in March 2026.

Insulet

Insulet, headquartered in Acton, Massachusetts, makes the tubeless Omnipod pod systems. On 18 March 2025 the company said Omnipod 5 was commercially available in Australia and works with Dexcom G6 and G7 sensors, with Abbott's FreeStyle Libre 2 Plus support planned. Because pumps are largely self-funded, the sector's February 2026 request for AUD 298.95 million of pump subsidies bears directly on its Australian growth.

Medtronic

Medtronic, headquartered in Dublin, Ireland, sells MiniMed insulin pumps and Guardian sensors through Medtronic Australasia. Its diabetes business MiniMed filed for a public share offering on 19 December 2025, after the separation was announced in May 2025. In December 2025 it began a United States launch of the MiniMed 780G with the Abbott-made Instinct sensor, signalling a more open sensor strategy that could widen Australian choice.

Other players operating in the Australia diabetes devices market include Ypsomed, Roche Diabetes Care, Tandem Diabetes Care, Embecta, and Ascensia Diabetes Care, alongside distributors, insulin makers supplying pens, private-label meter brands and online retailers supplying pharmacies, clinics and patients across Australia.

Key Insight

Competition rests on subsidy listings, device compatibility, clinician training and reliability rather than price alone, while integration between sensors and pumps decides which suppliers retain users.